EA
PASG icon

Emerald Advisers’s Passage Bio PASG Stock Holding History

Emerald Advisers’s Portfolio PASG Stock Details PASG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-7,035
Closed -$1.4M – 291
2021
Q3 		$1.4M Sell
7,035
-17,762
-72% -$4.24M 0.05% 142
2021
Q2 		$6.57M Sell
24,797
-180
-0.7% -$55.7K 0.24% 117
2021
Q1 		$8.73M Buy
24,977
+7,942
+47% +$3.39M 0.32% 108
2020
Q4 		$8.71M Sell
17,035
-46
-0.3% -$18.4K 0.29% 108
2020
Q3 		$4.48M Sell
17,081
-556
-3% -$191K 0.18% 115
2020
Q2 		$9.64M Sell
17,637
-93
-0.5% -$41.8K 0.42% 89
2020
Q1 		$5.58M Buy
+17,730
New +$5.55M 0.32% 94

Other funds holding PASG

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Emerald Advisers's PASG Position: Q4 2021 in Review

Emerald Advisers sold out of Passage Bio (PASG) in Q4 2021, closing a stake of 7,035 shares — an estimated $1.4M sold.

Emerald Advisers first reported a position in PASG in Q1 2020 and held it in 7 quarters. The position peaked at $9.64M in Q2 2020. 99 funds tracked by Wall St. Rank hold PASG as of Q4 2021.

  • Emerald Advisers reported no remaining Passage Bio position as of Q4 2021 after selling out during the quarter.
  • Emerald Advisers sold 7,035 Passage Bio shares in Q4 2021, an estimated $1.4M.
  • Emerald Advisers first reported a position in Passage Bio in Q1 2020 and held it in 7 quarters.
  • Emerald Advisers's Passage Bio position peaked at $9.64M in Q2 2020.
  • 99 funds tracked by Wall St. Rank held Passage Bio as of Q4 2021.

Based on Emerald Advisers's 13F filing for Q4 2021, filed 2 Feb 2022.